JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
85 hedge funds and large institutions have $39M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
85
Holding in Top 10
–
Calls
$9K
Puts
$6K
Top Buyers
| 1 | +$3.62M | |
| 2 | +$2.03M | |
| 3 | +$677K | |
| 4 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$394K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$331K |
Top Sellers
| 1 | -$4.16M | |
| 2 | -$2.69M | |
| 3 | -$1.61M | |
| 4 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$1.15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$851K |